These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23722322)

  • 21. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
    Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D; Gilden D
    Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract]   [Full Text] [Related]  

  • 23. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 24. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
    Fox RJ
    Mult Scler; 2013 Jan; 19(1):24-5. PubMed ID: 23303880
    [No Abstract]   [Full Text] [Related]  

  • 25. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C; Tintoré M; Aguilera C
    Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
    [No Abstract]   [Full Text] [Related]  

  • 26. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grey matter atrophy in patients suffering from multiple sclerosis.
    Kincses ZT; Tóth E; Bankó N; Veréb D; Szabó N; Csete G; Faragó P; Király A; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Sep; 67(9-10):293-300. PubMed ID: 25518257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
    Daelman L; Maitrot A; Maarouf A; Chaunu MP; Papeix C; Tourbah A
    Mult Scler; 2012 Nov; 18(11):1647-9. PubMed ID: 22907938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avoiding infusion therapy prime benefit of new MS drug.
    Morrow T
    Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
    [No Abstract]   [Full Text] [Related]  

  • 30. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J; Kümpfel T; Hohlfeld R
    Dtsch Med Wochenschr; 2012 Apr; 137(17):894-9. PubMed ID: 22492476
    [No Abstract]   [Full Text] [Related]  

  • 32. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognizing and overcoming potential barriers to oral medications for MS.
    Moses H
    J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N; Tambour M; Henriksson F; Fredrikson S
    J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.
    Clin Infect Dis; 2013 Oct; 57(8):ii. PubMed ID: 24195115
    [No Abstract]   [Full Text] [Related]  

  • 37. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
    JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
    [No Abstract]   [Full Text] [Related]  

  • 38. Fingolimod. Mitsubishi Pharma/Novartis.
    Dumont FJ
    IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fingolimod - a new immunomodulator].
    Friedrich FW; Eschenhagen T
    Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.